Ustekinumab. Análisis de efectos adversos infecciosos
Ustekinumab. Analysis of Rates of Infection
P. Herranz-Pinto
, E. Sendagorta
Autor para correspondencia
Servicio de Dermatología. Hospital Universitario La Paz. Madrid. España
Leído
5403
Vecesse ha leído el artículo
2597
Total PDF
2806
Total HTML
| año/Mes | Html | Total | |
|---|---|---|---|
| 2025 6 | 70 | 118 | 188 |
| 2025 5 | 106 | 56 | 162 |
| 2025 4 | 300 | 37 | 337 |
| 2025 3 | 70 | 33 | 103 |
| 2025 2 | 64 | 17 | 81 |
| 2025 1 | 54 | 36 | 90 |
| 2024 12 | 37 | 21 | 58 |
| 2024 11 | 49 | 58 | 107 |
| 2024 10 | 31 | 37 | 68 |
| 2024 9 | 29 | 22 | 51 |
| 2024 8 | 49 | 44 | 93 |
| 2024 7 | 41 | 27 | 68 |
| 2024 6 | 55 | 28 | 83 |
| 2024 5 | 47 | 45 | 92 |
| 2024 4 | 44 | 31 | 75 |
| 2024 3 | 29 | 30 | 59 |
| 2024 2 | 23 | 27 | 50 |
| 2024 1 | 18 | 25 | 43 |
| 2023 12 | 22 | 17 | 39 |
| 2023 11 | 26 | 21 | 47 |
| 2023 10 | 24 | 18 | 42 |
| 2023 9 | 22 | 27 | 49 |
| 2023 8 | 26 | 22 | 48 |
| 2023 7 | 21 | 26 | 47 |
| 2023 6 | 12 | 33 | 45 |
| 2023 5 | 9 | 22 | 31 |
| 2023 4 | 17 | 25 | 42 |
| 2023 3 | 15 | 33 | 48 |
| 2023 2 | 17 | 22 | 39 |
| 2022 1 | 17 | 31 | 48 |
| 2022 12 | 22 | 39 | 61 |
| 2022 11 | 23 | 34 | 57 |
| 2022 10 | 69 | 26 | 95 |
| 2022 9 | 49 | 40 | 89 |
| 2022 8 | 44 | 45 | 89 |
| 2022 7 | 22 | 45 | 67 |
| 2022 6 | 15 | 55 | 70 |
| 2022 5 | 22 | 38 | 60 |
| 2022 4 | 31 | 30 | 61 |
| 2022 3 | 20 | 42 | 62 |
| 2022 2 | 20 | 26 | 46 |
| 2021 1 | 21 | 36 | 57 |
| 2021 12 | 15 | 32 | 47 |
| 2021 11 | 22 | 41 | 63 |
| 2021 10 | 21 | 51 | 72 |
| 2021 9 | 20 | 44 | 64 |
| 2021 8 | 25 | 28 | 53 |
| 2021 7 | 11 | 24 | 35 |
| 2021 6 | 19 | 49 | 68 |
| 2021 5 | 18 | 40 | 58 |
| 2021 4 | 49 | 63 | 112 |
| 2021 3 | 42 | 39 | 81 |
| 2021 2 | 26 | 24 | 50 |
| 2020 1 | 25 | 13 | 38 |
| 2020 12 | 15 | 17 | 32 |
| 2020 11 | 10 | 17 | 27 |
| 2020 10 | 24 | 12 | 36 |
| 2020 9 | 11 | 6 | 17 |
| 2020 8 | 21 | 13 | 34 |
| 2020 7 | 19 | 11 | 30 |
| 2020 6 | 24 | 22 | 46 |
| 2020 5 | 21 | 32 | 53 |
| 2020 4 | 20 | 15 | 35 |
| 2020 3 | 25 | 17 | 42 |
| 2020 1 | 0 | 5 | 5 |
| 2019 12 | 0 | 3 | 3 |
| 2019 11 | 0 | 1 | 1 |
| 2019 10 | 0 | 2 | 2 |
| 2019 9 | 0 | 5 | 5 |
| 2019 8 | 0 | 1 | 1 |
| 2019 7 | 0 | 6 | 6 |
| 2019 6 | 0 | 3 | 3 |
| 2019 5 | 0 | 23 | 23 |
| 2019 4 | 0 | 25 | 25 |
| 2019 2 | 1 | 5 | 6 |
| 2019 1 | 0 | 3 | 3 |
| 2018 12 | 1 | 7 | 8 |
| 2018 11 | 0 | 2 | 2 |
| 2018 10 | 0 | 3 | 3 |
| 2018 8 | 0 | 6 | 6 |
| 2018 6 | 0 | 4 | 4 |
| 2018 2 | 13 | 5 | 18 |
| 2018 1 | 12 | 4 | 16 |
| 2017 12 | 12 | 9 | 21 |
| 2017 11 | 10 | 7 | 17 |
| 2017 10 | 8 | 5 | 13 |
| 2017 9 | 9 | 7 | 16 |
| 2017 8 | 6 | 10 | 16 |
| 2017 7 | 12 | 3 | 15 |
| 2017 6 | 14 | 6 | 20 |
| 2017 5 | 8 | 9 | 17 |
| 2017 4 | 18 | 16 | 34 |
| 2017 3 | 11 | 25 | 36 |
| 2017 2 | 9 | 9 | 18 |
| 2016 1 | 10 | 21 | 31 |
| 2016 12 | 23 | 11 | 34 |
| 2016 11 | 23 | 12 | 35 |
| 2016 10 | 22 | 9 | 31 |
| 2016 9 | 30 | 13 | 43 |
| 2016 8 | 29 | 15 | 44 |
| 2016 7 | 18 | 8 | 26 |
| 2016 6 | 0 | 4 | 4 |
| 2016 5 | 0 | 9 | 9 |
| 2016 4 | 1 | 1 | 2 |
| 2016 3 | 0 | 2 | 2 |
| 2016 2 | 0 | 4 | 4 |
| 2015 1 | 0 | 16 | 16 |
| 2015 12 | 0 | 19 | 19 |
| 2015 11 | 5 | 16 | 21 |
| 2015 10 | 3 | 5 | 8 |
| 2015 9 | 5 | 13 | 18 |
| 2015 8 | 6 | 7 | 13 |
| 2015 7 | 22 | 3 | 25 |
| 2015 6 | 21 | 3 | 24 |
| 2015 5 | 45 | 19 | 64 |
| 2015 4 | 30 | 12 | 42 |
| 2015 3 | 26 | 20 | 46 |
| 2015 2 | 29 | 10 | 39 |
| 2015 1 | 33 | 12 | 45 |
| 2014 12 | 34 | 8 | 42 |
| 2014 11 | 23 | 11 | 34 |
| 2014 10 | 34 | 29 | 63 |
| 2014 9 | 0 | 2 | 2 |
| 2014 5 | 1 | 0 | 1 |
| 2014 1 | 0 | 1 | 1 |
| 2013 9 | 1 | 1 | 2 |
| 2013 6 | 0 | 1 | 1 |
| 2013 5 | 1 | 1 | 2 |
| 2013 4 | 1 | 2 | 3 |
| 2013 2 | 1 | 2 | 3 |
| 2013 1 | 0 | 1 | 1 |
Mostrar todo
